A frameless SRS patient treatment was planned with BrainLab Iplan RT dose 4.1.3. The plan was intended for treatment of intra-cranial metastatic lesions located in 3 different regions/isocenters. The customer prescribed 100% dose to 99% of the volume to all three PTVS (defined as "hard constraints").